Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1998-04-09
1999-11-09
Robinson, Allen J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514375, 514411, 514413, 514416, 514428, 514448, 514494, A61K 3119, A61K 3138, A61K 3140, A61K 3142
Patent
active
059815922
ABSTRACT:
A composition for use in preventing colorectal cancer and other neoplastic diseases, such as breast cancer, includes an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof in an amount effective to elicit a chemoprotective effect. The composition is substantially free of the S-enantiomer of the R-NSAID. Therapeutic use of the composition is accompanied by reduced adverse side effects. A method of treating cystic fibrosis likewise includes the step of administering to a patient in need of such treatment a composition having an effective cystic fibrosis therapeutic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.
REFERENCES:
patent: 3755427 (1973-08-01), Adams et al.
patent: 4983765 (1991-01-01), Lukas et al.
patent: 5200198 (1993-04-01), Geisslinger et al.
patent: 5206029 (1993-04-01), Brune et al.
patent: 5331000 (1994-07-01), Young et al.
patent: 5382591 (1995-01-01), Barberich et al.
patent: 5560924 (1996-10-01), Wunderlich et al.
W.J. Wechter: "Drug Chirality: On the Mechanism of R-Aryl Propionic Acid Class NSAIDs. Epimerization in Humans and the Clinical Implications for the Use of Racemates." J. Clin. Pharmacol., vol. 34, No. 11, 1994, pp. 1036-1042.
W.J. Wechter: "Rac-Flurbiprofen is More Ulcerogenic than its (S)-Enantiomer." Chirality, vol. 5, No. 7, 1993 pp. 492-494.
Hixson et al., Cancer Epidemiol., Biomarkers Prev. (1994) 3(5), 433-8 Abstract Only.
Menzel-Soglowek et al., "Metabolic Chiral Inversion of 2-Arylpropionates in Different Tumor Cell Lines", Variability in Response to Anti-Rheumatic Drugs/Agents and Action Supplements, vol. 44, 1993, pp. 23-29.
Heath, et al., "Nonsteroial Antiinflammatory Drugs and Human Cancer," Cancer, 1994; 74:2885-8.
Waterhouse, et al., "Aspirin, NSAIDs, and Risk Reduction of Colorectal Cancer", Arch Intern Med, vol. 154, Feb. 28, 1994; pp. 366-368.
Lipkin, "Biomakers of Increased Susceptibility to Gastrointestinal Cancer: New Application to Studies of Cancer Prevention in Human Subjects", Cancer Research 48, Jan. 15, 1988; pp. 235-245.
Konstan, et al., "Effect of High-Dose Ibuprofen in Patients With Cystic Fibrosis", The New England Journal of Medicine, Mar. 30, 1995; pp. 848-854.
Moertel, et al., "Levamisole and Fluroouracil for Adjuvant Therapy of Resected Colon Carcinoma", New England Journal of Medicine, 1990; 322:352-8.
Marnett, "Aspirin and the Potential Role of Prostaglandins in Colon Cancer," Cancer Research, 1992; 52:5575-89.
Welberg et al., "Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A Refined Immunohistochemical Method", J. Clin Pathol, 1990; 43:453-456.
Thun et al., "Aspirin Use and Reduced Risk of Fatal Colon Cancer," N Engl J Med 1991; 325:1593-6.
Peleg, et al., "Aspirin and Nonsteroidal Antiflammatory Drug Use and the Risk of Subsequent Colorectal Cancer" Arch Intern Med, 1994; 154:394-9.
Gridley, et al., "Incidence of Cancer Among Patients With Rheumatoid Arthritis", J Natl Cancer Inst, 1993; 85:307-311.
Labayle, et al., "Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous Polyposis", Gastoenterology, 1991; 101:635-639.
Rigau, et al., "Effects of Long-Term Sulindac Therapy on Colonic Polyposis", Annals of Internal Medicine, 1991 115:952-954.
Giardiello, et al., "Treatment of Colonic and Rectal Adenomas With Sulindac in Familial Adenomatous Polyposis" N Engl J Med, 1993; 328:1313-6.
Pollard, et al., "Effect of Indomethacin on Intestinal Tumors Induced in Rats by the Acetate Derivative of Dimethylnitrosamine"; Science, Oct. 30, 1981; vol. 214, pp. 558-559.
Reddy, et al., "Inhibitory Effect on Aspirin on Azoxymethane-Induced Colon Carcinogenesis in F344 Rats", Carcinogenesis, 1993; vol. 14, No. 8, pp. 1493-1497.
Gibaldi et al., Pharmacokinetics, 1982, Chapter 1, pp. 1-5.
Jamali, "Pharmacokinetics of Enantiomers of Chiral Non-Steroidal Anti-Inflammatory Drugs", Eur J Drug Metab Pharmacokin, 1988; vol. 13, No. 1, pp. 1-9.
McCracken John D.
Wechter William J.
Loma Linda University Medical Center
Robinson Allen J.
LandOfFree
Method and composition for treating cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treating cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating cystic fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456779